{"preliminary_commentary":{"by_channel":{"youtube":10,"podcast":5,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05730036\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["linvoseltamab"]],"indication":"relapsed/refractory multiple myeloma","name":"LINKER-MM3","nct_id":"NCT05730036","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=linker-mm3-nct05730036. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LINKER-MM3","arms":[{"description":"Randomization 1:1","label":"Linvoseltamab","type":"EXPERIMENTAL"},{"description":"Randomization 1:1","label":"Elotuzumab/Pomalidomide/Dexamethasone (EPd)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2033-04-19","type":"ESTIMATED"},"conditions":["Relapsed Refractory Multiple Myeloma (RRMM)"],"enrollment":{"count":410,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Linvoseltamab","otherNames":["REGN5458","Lynozyfic™"],"type":"DRUG"},{"name":"Elotuzumab","otherNames":["Empliciti"],"type":"DRUG"},{"name":"Pomalidomide","otherNames":["Pomalyst"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":["Decadron"],"type":"DRUG"}],"last_update":"2026-10-07","lead_sponsor":"Regeneron Pharmaceuticals","official_title":"An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2033-04-19","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC) in CD38 antibody exposed participants","timeFrame":"Up to approximatively 5 years"}],"references":[],"start_date":{"date":"2023-09-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT05730036"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/linker-mm3-nct05730036"}